Pelin Akbas

Dr. Pelin Akbas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
PAPelin Akbas
Pelin Akbas
SBSibel Bektas
Sibel Bektas
GYGokhan Yazici
Gokhan Yazici

1 January 2021 in Turkish Journal of Pathology
Verified
Journal Article
Open access
EKElife Kimiloglu
Elife Kimiloglu
PAPelin Akbas
Pelin Akbas
OOOzgul Esen Ore
Ozgul Esen Ore
CTCagla Turan
Cagla Turan
Lafora disease is a severe form of progressive myoclonic epilepsy with autosomal recessive inheritance diagnosed by inclusion body in biopsy. A 26-year-old woman was admitted due to complaints of frequent twitches and fainting. The 0.5x0.3x0.3 cm axillary skin punch biopsy was subjected to routine histopathological evaluation. Cytoplasmic PAS-positive inclusion bodies were observed at the basal side of the eccrine and apocrine glands. The diagnosis of Lafora disease can also be made by the observation of the polyglycosan cytoplasmic inclusion bodies in the brain, liver and skeletal muscle biopsies. Although we need more work to understand the etiopathogenesis of Lafora disease, we would like to draw attention to the importance of skin biopsy in the differential diagnosis of young patients with clinically refractory epilepsy, myoclonus, and cognitive decline.


18 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EYEmine Yıldırım
Emine Yıldırım
PAPelin Akbas
Pelin Akbas
SBSibel Bektaş
Sibel Bektaş
ASadem senturk
adem senturk
PBPelin Basim
Pelin Basim
MKMustafa Uygar Kalaycı
Mustafa Uygar Kalaycı
Background/Objectives: Bethesda category III (atypia of undetermined significance/follicular lesion of undetermined significance; AUS/FLUS) thyroid nodules represent a heterogeneous group with variable malignancy risk, creating challenges in clinical management. This study aimed to evaluate the associations of preoperative ultrasonographic findings, inflammation-based hematological markers, and cytological atypia subtypes with final histopathological outcomes in surgically treated Bethesda III thyroid nodules. Methods: This retrospective study included 72 adult patients with Bethesda III thyroid nodules who underwent thyroid surgery between January 2020 and December 2025. Demographic characteristics, ultrasonographic findings, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), cytological atypia subtypes, and final histopathological diagnoses were analyzed. Univariate and multivariable logistic regression analyses were performed to identify predictors of malignancy. Results: Final histopathological examination revealed benign lesions in 49 patients (68.1%) and malignant lesions in 23 patients (31.9%). Age, sex, nodule size, multinodular goiter, Hashimoto thyroiditis, microcalcifications, hypoechogenicity, suspicious margins, and TI-RADS category were not significantly associated with malignancy (all p > 0.05). Similarly, NLR and PLR did not differ significantly between benign and malignant nodules (NLR: 1.80 vs. 1.98, p = 0.319; PLR: 117.9 vs. 135.0, p = 0.398). Among cytological atypia subtypes, nuclear atypia demonstrated the highest malignancy rate (50.0%) and was significantly associated with malignant histopathological outcomes (OR = 3.364, 95% CI: 1.182–9.570, p = 0.023). After adjustment for age and biopsied nodule size, nuclear atypia remained an independent predictor of malignancy (adjusted OR = 3.963, 95% CI: 1.298–12.094, p = 0.016). Conclusions: In surgically treated Bethesda III thyroid nodules, nuclear atypia was the only independent predictor of malignancy, whereas ultrasonographic characteristics, NLR, and PLR showed limited predictive value. Subclassification of Bethesda III nodules according to cytological atypia may improve preoperative risk stratification and support clinical decision-making. Because the study included only surgically treated patients, the findings should be interpreted in the context of a surgically selected cohort and may not be generalizable to the overall Bethesda III population.

22 July 2026 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PAPelin Akbas
Pelin Akbas
SBSibel Bektaş
Sibel Bektaş
MGMucahit Gelmis
Mucahit Gelmis
FBFerhat Berker
Ferhat Berker
Background: Sarcomatoid carcinoma of the prostate is a rare and aggressive biphasic malignancy, typically arising in the setting of prior prostatic adenocarcinoma. Prominent heterologous differentiation may obscure its epithelial origin and lead to diagnostic confusion with primary mesenchymal tumors. Case presentation: We report an 80-year-old man with a history of metastatic prostate adenocarcinoma treated with androgen deprivation therapy, who presented with acute urinary obstruction and low prostate-specific antigen levels. Transurethral resection revealed a highly heterogeneous tumor composed of extensive cartilaginous and high-grade sarcomatoid components, including both chondrosarcomatous and osteosarcomatous differentiation. Despite thorough histopathological examination, no epithelial component was identified. Prior pathology confirmed adenocarcinoma up to 9 months earlier, with evidence of sarcomatoid transformation emerging in recent specimens. Immunohistochemistry supported mesenchymal differentiation. Based on clinicopathological correlation, a diagnosis of sarcomatoid carcinoma of the prostate with heterologous differentiation was established. Conclusion: This report highlights a significant diagnostic pitfall in which sarcomatoid carcinoma may mimic primary sarcoma when the sarcomatoid component predominates and epithelial elements are absent. It also underscores the potential role of androgen deprivation therapy in tumor dedifferentiation and the limitations of PSA in monitoring disease progression. Awareness of this entity is essential for accurate diagnosis and appropriate clinical management.